Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parexel and Proteome Sciences have announced the formation of an alliance focused on enhancing Parexel's biomarker capabilities for early phase clinical development. Parexel is using Proteome Sciences' PS Biomarker Services protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.
Subscribe to our email newsletter
Proteome Sciences will assist Parexel early phase experts in helping biopharmaceutical companies advance biomarker discovery and qualification within clinical trials. This expanded capability allows Parexel to offer its customers mass spectrometric and pharmacokinetic assays for protein and peptide compounds.
Parexel early phase experts provide deep scientific insights and a broad portfolio of biomarkers and non-routine laboratory analysis. With its alliance partners, Parexel helps biopharmaceutical companies select and interpret the right biomarkers. Parexel provides access to key biomarkers in major disease categories, including oncology, hematology, neurology, cardiology, infectious diseases, endocrinology, respiratory, gastroenterology, urology and immunology.
The company’s early phase units offer fully validated analytical methods, including a broad scope of cellular and soluble biomarker analysis capabilities, and bioanalytical services for qualitative and quantitative drug, metabolite, and biomarker analysis in a variety of matrices.
Michelle Middle, corporate vice president and worldwide head of early phase at Parexel, said: “Biomarker analyses are anticipated to become increasingly important in clinical trials to understand the biological activity and safety profile of candidate therapies. Our early phase experts are focused on helping customers make better decisions faster about their compounds in development. Biopharmaceutical companies benefit from our bioanalytical and biomarker capabilites to generate reproducible and reliable data that can be interpreted for pharmacokinetic or pharmacodynamic purposes.
“Our alliance with Proteome Sciences reinforces our commitment to provide customers with significant expertise to help them select relevant biomarkers for their development programs, interpret results, and determine implications for their therapies.”
Christopher Pearce, chief executive of Proteome, said: “We are very pleased to have PS Biomarker Services selected by Parexel as a preferred provider of protein and peptide biomarker services. We believe that the current regulatory requirements for biomarkers in drug development and diagnostics coupled with the need for fast, flexible and cost effective workflows have meant that specialist services will be increasingly required. Our ISO 9001:2008 facility in Frankfurt, Germany was designed to provide expert protein biomarker discovery and validation and for the development of rapid mass spectrometric-based assays to service the growing requirements of the biopharmaceutical industry.”